United States Population Disparities in Ophthalmic Care: Blindness and Visual Impairment in the IRIS® Registry (Intelligent Research in Sight)
- PMID: 37331480
- PMCID: PMC10592479
- DOI: 10.1016/j.ophtha.2023.06.011
United States Population Disparities in Ophthalmic Care: Blindness and Visual Impairment in the IRIS® Registry (Intelligent Research in Sight)
Abstract
Purpose: To evaluate associations of patient characteristics with United States eye care use and likelihood of blindness.
Design: Retrospective observational study.
Participants: Patients (19 546 016) with 2018 visual acuity (VA) records in the American Academy of Ophthalmology's IRIS® Registry (Intelligent Research in Sight).
Methods: Legal blindness (20/200 or worse) and visual impairment (VI; worse than 20/40) were identified from corrected distance acuity in the better-seeing eye and stratified by patient characteristics. Multivariable logistic regressions evaluated associations with blindness and VI. Blindness was mapped by state and compared with population characteristics. Eye care use was analyzed by comparing population demographics with United States Census estimates and proportional demographic representation among blind patients versus a nationally representative US population sample (National Health and Nutritional Examination Survey [NHANES]).
Main outcome measures: Prevalence and odds ratios for VI and blindness; proportional representation in the IRIS® Registry, Census, and NHANES by patient demographics.
Results: Visual impairment was present in 6.98% (n = 1 364 935) and blindness in 0.98% (n = 190 817) of IRIS patients. Adjusted odds of blindness were highest among patients ≥ 85 years old (odds ratio [OR], 11.85; 95% confidence interval [CI], 10.33-13.59 vs. those 0-17 years old). Blindness also was associated positively with rural location and Medicaid, Medicare, or no insurance vs. commercial insurance. Hispanic (OR, 1.59; 95% CI, 1.46-1.74) and Black (OR, 1.73; 95% CI, 1.63-1.84) patients showed a higher odds of blindness versus White non-Hispanic patients. Proportional representation in IRIS Registry relative to the Census was higher for White than Hispanic (2- to 4-fold) or Black (11%-85%) patients (P < 0.001). Blindness overall was less prevalent in NHANES than IRIS Registry; however, prevalence in adults aged 60+ was lowest among Black participants in the NHANES (0.54%) and second highest among comparable Black adults in IRIS (1.57%).
Conclusions: Legal blindness from low VA was present in 0.98% of IRIS patients and associated with rural location, public or no insurance, and older age. Compared with US Census estimates, minorities may be underrepresented among ophthalmology patients, and compared with NHANES population estimates, Black individuals may be overrepresented among blind IRIS Registry patients. These findings provide a snapshot of US ophthalmic care and highlight the need for initiatives to address disparities in use and blindness.
Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Keywords: Blindness; Health care disparities; IRIS Registry.
Published by Elsevier Inc.
Conflict of interest statement
Dr. S. Pershing reports consulting fees/equity from Acumen, LLC, and Verana Health, outside the submitted work.
Dr. A. Lee reports grants from Santen, Carl Zeiss Meditec, and Novartis, personal fees from Genentech, Topcon, and Verana Health, outside of the submitted work.
Dr. A. Lorch reports consulting fees from Regeneron.
Dr. D. Parke II reports employee of American Academy of Ophthalmology and Board, Verana Health.
Dr. J. Miller reports consulting fees (KalVista Pharmaceuticals, Sunovion, Heidelberg Engineering, ONL Therapeutics), royalties (Valeant Pharmaceuticals/Mass Eye and Ear), patents/intellectual property (Valeant Pharmaceuticals/Mass Eye and Ear, ONL Therapeutics, Drusolv Therapeutics), stock options/equity (ONL Therapeutics, Aptinyx, Inc., Ciendias Bio).
Figures


Similar articles
-
Vision Impairment and Blindness Prevalence in the United States: Variability of Vision Health Responses across Multiple National Surveys.Ophthalmology. 2021 Jan;128(1):15-27. doi: 10.1016/j.ophtha.2020.06.064. Epub 2020 Jul 11. Ophthalmology. 2021. PMID: 32663529 Free PMC article.
-
Corneal Opacity in the United States: An American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) Study.Ophthalmology. 2025 Jan;132(1):52-61. doi: 10.1016/j.ophtha.2024.07.005. Epub 2024 Jul 8. Ophthalmology. 2025. PMID: 38986874
-
Causes of Childhood Blindness in the United States Using the IRIS® Registry (Intelligent Research in Sight).Ophthalmology. 2023 Sep;130(9):907-913. doi: 10.1016/j.ophtha.2023.04.004. Epub 2023 Apr 8. Ophthalmology. 2023. PMID: 37037315 Free PMC article.
-
Amblyopia Outcomes Through Clinical Trials and Practice Measurement: Room for Improvement: The LXXVII Edward Jackson Memorial Lecture.Am J Ophthalmol. 2020 Nov;219:A1-A26. doi: 10.1016/j.ajo.2020.07.053. Epub 2020 Aug 7. Am J Ophthalmol. 2020. PMID: 32777377 Review.
-
The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data.Ophthalmology. 2018 Aug;125(8):1149-1159. doi: 10.1016/j.ophtha.2018.02.005. Epub 2018 Mar 13. Ophthalmology. 2018. PMID: 29548645 Review.
Cited by
-
Big data and electronic health records for glaucoma research.Taiwan J Ophthalmol. 2024 Sep 13;14(3):352-359. doi: 10.4103/tjo.TJO-D-24-00055. eCollection 2024 Jul-Sep. Taiwan J Ophthalmol. 2024. PMID: 39430348 Free PMC article. Review.
-
Loss to Follow-Up and Risk of Incident Blindness among Patients with Glaucoma in the IRIS® Registry.Ophthalmol Glaucoma. 2025 May 8:S2589-4196(25)00104-8. doi: 10.1016/j.ogla.2025.05.001. Online ahead of print. Ophthalmol Glaucoma. 2025. PMID: 40348057
-
Transforming retinal disease management through diabetes care.J Manag Care Spec Pharm. 2025 Apr;31(4-a Suppl):S1-S11. doi: 10.18553/jmcp.2025.31.4-a.s1. J Manag Care Spec Pharm. 2025. PMID: 40152815 Free PMC article.
-
Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.J Manag Care Spec Pharm. 2025 May;31(5):451-460. doi: 10.18553/jmcp.2025.24340. Epub 2025 Apr 3. J Manag Care Spec Pharm. 2025. PMID: 40177921 Free PMC article.
-
Vision Loss and Blindness in the United States: An Age-Adjusted Comparison by Sex and Associated Disease Category.Ophthalmol Sci. 2025 Feb 7;5(4):100735. doi: 10.1016/j.xops.2025.100735. eCollection 2025 Jul-Aug. Ophthalmol Sci. 2025. PMID: 40212928 Free PMC article.
References
-
- Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci. 2002;43(11):3393–3398. - PubMed
-
- Zwerling C, Whitten PS, Davis CS, Sprince NL. Occupational injuries among older workers with visual, auditory, and other impairments. A validation study. J Occup Environ Med. 1998;40(8):720–723. - PubMed
-
- Nastasi JA. The everyday lives of older adults with visual impairment: An occupational perspective. Br J Occup Ther. 2018;81(5):266–275.
-
- Tsai SY, Cheng CY, Hsu WM, Su TPT, Liu JH, Chou P. Association between visual impairment and depression in the elderly. J Formos Med Assoc. 2003;102(2):86–90. - PubMed
-
- Hayman KJ, Kerse NM, La Grow SJ, Wouldes T, Robertson MC, Campbell AJ. Depression in older people: visual impairment and subjective ratings of health. Optom Vis Sci. 2007;84(11):1024–1030. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical